Biotech Values

[DewDiligence]

Excellent post, IMO, on multiple counts. I think you’re correct that: i) BMY has an out if INX-189 runs into safety problems before the deal closes; ii) the timing of the announcement was predicated on HSR clearance for GILD-VRUS; and iii) Monday will likely be a good shorting opportunity for some HCV names.